Drug intelligence / Profile preview

LR19157

Development stage: Preclinical
Lead developer: LG Chem
Modality: Small Molecules

Overview

LR19157 is a preclinical small molecule inhibitor targeting the CBP/p300 (CREB-binding protein and p300) acetyltransferase activity. Developed by AVEO Oncology (an LG Chem company), it is being investigated for the treatment of Acute Myeloid Leukemia (AML). CBP and p300 are closely related transcriptional co-activators that play critical roles in cell growth and differentiation; their dysregulation is often implicated in various hematological malignancies. By inhibiting these targets, LR19157 aims to modulate gene expression patterns that drive leukemic cell proliferation.

Targets

EP300 (Histone acetyltransferase p300)CREBBP (CREB-binding protein)

Beyond the preview

Go deeper on LR19157.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LR19157.

Explore the full profile